GlassScriptPhysician profile
Joseph B Hill
NPI 1427108158
$1,607.47
in general payments reported to CMS, 2019-2025
27 companies · $91.02 in 2025
The $91.02 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $235 · 2021: $319 · 2022: $153 · 2023: $283 · 2024: $179 · 2025: $91.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $256.71 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $181.43 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $132.55 | 2019-2024 | Otezla, Repatha, Tepezza |
| Sanofi-Aventis U.S. LLC | $126.64 | 2019-2021 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Amarin Pharma, INC. | $99.00 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $66.69 | 2023-2024 | Gemtesa |
| Abbvie INC. | $58.79 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $51.76 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $49.35 | 2023-2024 | Gvoke Hypopen |
| Dexcom, INC. | $44.08 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $43.33 | 2020-2021 | |
| Allergan, INC. | $42.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.00 | 2023 | |
| Insulet Corporation | $33.12 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $31.11 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $31.05 | 2022-2024 | Trelegy Ellipta |
| Pfizer INC. | $30.86 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.96 | 2023-2025 | Xifaxan, Trulance |
| Arbor Pharmaceuticals, INC. | $25.70 | 2019 | |
| Edwards Lifesciences Corporation | $25.55 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $24.70 | 2019-2020 | |
| Scynexis, INC. | $17.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.84 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2023 | Synjardy, Jardiance, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.